Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 12/20 | 0.89 |
| ▸ | BCL2 | P10415 | 11/20 | 0.89 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 2/20 | 0.89 |
| ▸ | USP2 | O75604 | 2/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.89 |
| ▸ | POLB | P06746 | 2/20 | 0.89 |
| ▸ | GAA | P10253 | 2/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | THRB | P10828 | 2/20 | 0.89 |
| ▸ | HPGD | P15428 | 2/20 | 0.89 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.89 |
| ▸ | BLM | P54132 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920277 | 0.96 | MCL1 (0.81) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL30260519 | 0.94 | MCL1 (1.00) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL29798874 | 0.94 | MCL1 (1.00) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL29355719 | 0.94 | MCL1 (1.00) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL3939 | 0.94 | MCL1 (1.00) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL9738017 | 0.94 | MCL1 (1.00) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL23014699 | 0.93 | MCL1 (0.97) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL28855396 | 0.93 | MCL1 (0.97) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL27755741 | 0.93 | MCL1 (0.97) | MCL1BCL2AKR1B1KDM4EMEN1 | |
| Gossypol SCHEMBL28166062 | 0.93 | MCL1 (0.97) | MCL1BCL2AKR1B1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | KREOS CAPITAL V (EXPERT FUND) L.P. (JE) | 2018-08-09 | — | — | US | disclosed |
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | HOFFMANN-LA ROCHE INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | Hoffman-La Roche. Inc. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | ROCHE GLYCART AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056186-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | MCL1 13/4885BCL2 2/4885AKR1B1 1528/4885 |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | MCL1 13/4885BCL2 2/4885AKR1B1 1528/4885 |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | MCL1 13/4885BCL2 2/4885AKR1B1 1528/4885 |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | BAK1, BCL2, BCL3 | MCL1 13/4885BCL2 2/4885AKR1B1 1528/4885 |
| US-20180221393-A1 | CXCR4 BINDING AGENTS FOR TREATMENT OF DISEASES | CXCL12, CXCR4, CXCR1 | MCL1 7/4885BCL2 14/4885AKR1B1 3498/4885 |
| US-20090098118-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | MCL1 13/4885BCL2 2/4885AKR1B1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.